Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, C.-Y.
Right arrow Articles by Perng, P.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, C.-Y.
Right arrow Articles by Perng, P.-P.
(Chest. 2005;128:2088-2092.)
© 2005 American College of Chest Physicians

Effect of Oral Aminophylline on Pulmonary Function Improvement and Tolerability in Different Age Groups of COPD Patients*

Cheng-Yu Chen, MD; Kuang-Yao Yang, MD; Yu-Chin Lee, MD and Peury-Perng Perng, MD, PhD

* From the Institute of Emergency and Critical Medicine (Dr. Chen), Institute of Clinical Medicine (Dr. Yang), and School of Medicine (Dr. Lee), National Yang-Ming University; and Chest Department (Dr. Perng), Taipei Veterans General Hospital, Taipei, Taiwan, ROC.

Correspondence to: Kuang-Yao Yang, MD, Chest Department, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Rd, Taipei, Taiwan, ROC; e-mail: kyyang{at}vghtpe.gov.tw

Background: Aminophylline therapy in elderly patients with COPD is rarely studied. This study attempted to explore the symptoms, pulmonary function improvement, and adverse events related to aminophylline therapy in COPD patients of different age groups.

Methods and results: We designed a 10-week prospective study. Two groups of COPD patients were classified based on age (30 patients in group 1, 55 to 74 years old; 30 patients in group 2, 75 to 90 years old), with matched disease severity. After stopping all methylxanthines for 2 weeks in the washout period, therapy began with long-acting 225-mg aminophylline compounds bid po for 8 weeks. Pulmonary functions, respiratory symptoms, and laboratory examinations were checked at the initial visit and at every 4-week visit. After aminophylline therapy, the drug serum level showed no significant difference in either group (9.73 ± 6.35 mg/dL [± SD] in group 1 and 7.82 ± 6.68 mg/dL in group 2, p = 0.359). Improvements of FEV1 and FVC were noted in both groups; however, there was no significant difference. Peak expiratory flow rate (PEFR) was significantly improved in group 1 but not in group 2 (group 1, from 3.51 to 3.97 L/s, p < 0.05; group 2, from 2.78 to 3.08 L/s, p > 0.05). The degree of improvement in symptom scores was not different between the groups, except there was significantly less chest tightness in group 2 (from 0.79 ± 0.74 to 0.40 ± 0.50, p < 0.05). Electrolyte imbalance and arrhythmia did not appear in either group.

Conclusions: Our study demonstrated that the safety and drug concentration of aminophylline at a standard dose are not different in the sixth to ninth decades of COPD patients. Younger patients have more improvement in PEFR than older patients; however, older COPD patients have more symptoms relief in chest tightness after aminophylline therapy.

Key Words: age • aminophylline • COPD • pulmonary function • side effect






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.